Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: R-Pharm
• Treatments: Epothilones

Criteria

Inclusion Criteria:

• confirmed diagnosis of a primary solid tumor

• measurable or non-measurable disease

• progressive disease

• men and women greater or equal to 18 years of age.

Exclusion Criteria:

• women of child bearing potential who are not using birth control

• women who are pregnant or breast feeding

• women with a positive pregnancy test on enrollment

• patients with brain metastasis

• prior treatment with Ixabepilone

• known history of human immunodeficiency virus (HIV)